|
Neoplasm Metastasis
|
0.320 |
Biomarker
|
phenotype |
BEFREE |
Thus, ERp29 protected CRC cells from ERS‑mediated reduction of malignancy to promote metastasis and may be a potential target of medical intervention for CRC therapy.
|
30569094 |
2019 |
|
Neoplasm Metastasis
|
0.320 |
Biomarker
|
phenotype |
BEFREE |
Functional assays demonstrated that knockdown of ERp29 increased GC cell migration and invasion and promoted metastasis.
|
28874138 |
2017 |
|
Neoplasm Metastasis
|
0.320 |
Biomarker
|
phenotype |
CTD_human |
Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
|
17085005 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
BEFREE |
ERp29 is a novel target, which may be used to enhance the therapeutic effect of lung adenocarcinoma treatment with gemcitabine.
|
30651868 |
2019 |
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Overall, our study established a novel regulatory network of LncRNA MEG3/miR483-3p/ERp29 in HCC which may be helpful in better understanding the effect of high glucose on poor prognosis of HCC and in exploring new diagnostic and therapeutic tools for managing HCC in patients with diabetes.
|
31251997 |
2019 |
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS.
|
21472284 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.310 |
Biomarker
|
disease |
CTD_human |
Comparative proteome analysis of human adenocarcinoma.
|
19381893 |
2010 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In the present study, reverse transcription-quantitative polymerase chain reaction assays were used to analyze miR-195-5p and endoplasmic reticulum protein 29 (ERp29) levels in breast cancer and matched normal tissues.
|
31602229 |
2019 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Recently, the endoplasmic reticulum (ER) protein 29 (ERp29) has been shown to inversely associate with primary tumor development and function as a tumor suppressor in breast cancer.
|
28874138 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Targeting ERp29MGMT axis may be useful for providing better treatment efficacy in combination with radiotherapy in breast cancer.
|
26420420 |
2015 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK.
|
22064321 |
2012 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Here, we investigated whether ERp29 plays a role in the response of breast cancer cells to chemotherapeutic agents.
|
20833165 |
2010 |
|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In this study, we show that the expression of ERp29 was reduced with tumor progression in clinical specimens of breast cancer, and that overexpression of ERp29 resulted in G(0)/G(1) arrest and inhibited cell proliferation in MDA-MB-231 cells.
|
19770839 |
2009 |
|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
About 25% of breast cancers and also lactating mammary glands were expressing ERp29 while the resting glands did not.
|
18395818 |
2008 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
These findings suggest a tumor suppressive role of ERp29 in osteosarcoma.
|
30984555 |
2019 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In the present study, reverse transcription-quantitative polymerase chain reaction assays were used to analyze miR-195-5p and endoplasmic reticulum protein 29 (ERp29) levels in breast cancer and matched normal tissues.
|
31602229 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Thus, we conclude that ERp29 acts as a tumor suppressor gene in gastric cancer, and is expected to become a novel target of the treatment of GC.
|
29108263 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Recently, the endoplasmic reticulum (ER) protein 29 (ERp29) has been shown to inversely associate with primary tumor development and function as a tumor suppressor in breast cancer.
|
28874138 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Recently, the endoplasmic reticulum (ER) protein 29 (ERp29) has been shown to inversely associate with primary tumor development and function as a tumor suppressor in breast cancer.
|
28874138 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Targeting ERp29MGMT axis may be useful for providing better treatment efficacy in combination with radiotherapy in breast cancer.
|
26420420 |
2015 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK.
|
22064321 |
2012 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In this review, we summarize the biological properties of ERp29 and its novel function as a tumor suppressor.
|
20920593 |
2011 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Recently, we reported that ERp29 is a novel tumor suppressor and regulates mesenchymal-epithelial transition in MDA-MB-231 breast cancer cells.
|
20833165 |
2010 |